Glutamate, Dopamine, and Schizophrenia
暂无分享,去创建一个
[1] H. Crew. RECENT ADVANCES IN THE TEACHING OF PHYSICS. , 1904, Science.
[2] A. Carlsson,et al. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.
[3] P. Seeman,et al. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.
[4] S H Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.
[5] C. Carter,et al. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats , 1980, Nature.
[6] B. Angrist,et al. CNS stimulants as tools in the study of schizophrenia , 1984, Trends in Neurosciences.
[7] S. Stone-Elander,et al. Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[8] D. Weinberger. Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.
[9] D. Weinberger,et al. Mesocortical Dopaminergic Function and Human Cognition , 1988, Annals of the New York Academy of Sciences.
[10] L. Dwoskin,et al. Biphasic modulation of evoked [3H]D‐aspartate release by D‐2 dopamine receptors in rat striatal slices , 1988, Synapse.
[11] Ariel Y. Deutch,et al. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress , 1990, Brain Research.
[12] A. D. Smith,et al. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones , 1990, Trends in Neurosciences.
[13] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[14] J. Kleinman,et al. Characterization of [125I]SCH 23982 binding in human brain: Comparison with [3H]SCH 23390 , 1991, Neuroscience Letters.
[15] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[16] Douglas W. Jones,et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[17] H. Meltzer,et al. The mechanism of action of novel antipsychotic drugs. , 1991, Schizophrenia bulletin.
[18] C. Braestrup,et al. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. , 1992, European journal of pharmacology.
[19] A. Grace. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. , 1992, Journal of neural transmission. Supplementum.
[20] S. Nakanishi,et al. Molecular diversity and functions of glutamate receptors. , 1994, Annual review of biophysics and biomolecular structure.
[21] Philip D. Harvey,et al. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function , 1994, Schizophrenia Research.
[22] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[23] U. Ungerstedt,et al. Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid. , 1994, European journal of pharmacology.
[24] P S Goldman-Rakic,et al. D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Cooperman,et al. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[26] Alan C. Evans,et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] D. Javitt,et al. Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.
[28] R. Kötter. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum , 1994, Progress in Neurobiology.
[29] H. Holcomb,et al. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions , 1995, International clinical psychopharmacology.
[30] J. Hietala,et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.
[31] M. Starr. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson' disease , 1995, Synapse.
[32] J. Brotchie,et al. Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. , 1995, European journal of pharmacology.
[33] Karl J. Friston,et al. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia , 1995, Nature.
[34] Peter W. Kalivas,et al. Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress , 1995, Brain Research.
[35] Carol A. Tamminga,et al. Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.
[36] J. Olney,et al. Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.
[37] H. C. Cromwell,et al. Neuromodulatory actions of dopamine on synaptically‐evoked neostriatal responses in slices , 1996, Synapse.
[38] P. Goldman-Rakic,et al. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain , 1996, Nature.
[39] Charles J. Wilson,et al. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[40] E. Abercrombie,et al. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats , 1996, Brain Research Bulletin.
[41] F. Nicoletti,et al. Interaction Between A1 Adenosine and Class II Metabotropic Glutamate Receptors in the Regulation of Purine and Glutamate Release from Rat Hippocampal Slices , 1996, Journal of neurochemistry.
[42] J. Krystal,et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[43] J. Bargas,et al. D1 Receptor Activation Enhances Evoked Discharge in Neostriatal Medium Spiny Neurons by Modulating an L-Type Ca2+ Conductance , 1997, The Journal of Neuroscience.
[44] M. Iyo,et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.
[45] D. Schoepp,et al. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats , 1997, Neuroscience Letters.
[46] C. Crouzel,et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients , 1997, Schizophrenia Research.
[47] Bita Moghaddam,et al. Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.
[48] Anne W. Schmidt,et al. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. , 1997, European journal of pharmacology.
[49] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[50] D. Schoepp,et al. LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors , 1997, Neuropharmacology.
[51] P B Hoffer,et al. Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.
[52] D. Weinberger,et al. Dopamine, the prefrontal cortex and schizophrenia , 1997, Journal of psychopharmacology.
[53] Anthony A. Grace,et al. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs , 1997, Trends in Neurosciences.
[54] J. Krystal,et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.
[55] A. Deutch,et al. Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat. , 1998, The Journal of pharmacology and experimental therapeutics.
[56] H. Wikström,et al. Is clozapine an (partial) agonist at both dopamine D1 and D2 receptors? , 1998, Psychopharmacology.
[57] S. Kulkarni,et al. Partial agonistic action of clozapine at dopamine D2 receptors in dopamine depleted animals , 1998, Psychopharmacology.
[58] C. Cepeda,et al. Dopamine and N-Methyl-D- Aspartate Receptor Interactions in the Neostriatum , 1998, Developmental Neuroscience.
[59] Paul Greengard,et al. DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission , 1998 .
[60] Nicholas Lange,et al. D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.
[61] B. Moghaddam,et al. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.
[62] J Sandell,et al. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[63] N. Volkow,et al. Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects , 1998, Neuropsychopharmacology.
[64] D. Javitt,et al. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. , 1998, The international journal of neuropsychopharmacology.
[65] A. Malhotra,et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.
[66] J. Pin,et al. New perspectives for the development of selective metabotropic glutamate receptor ligands. , 1999, European journal of pharmacology.
[67] A. Sampson,et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.
[68] Hank P Jedema,et al. Clozapine Preferentially Increases Dopamine Release in the Rhesus Monkey Prefrontal Cortex Compared with the Caudate Nucleus , 1999, Neuropsychopharmacology.
[69] J. Seamans,et al. Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopamine in the Prefrontal Cortex , 1999, Neuropsychopharmacology.
[70] D. Wong,et al. GBR12909 attenuates amphetamine‐induced striatal dopamine release as measured by [11C]raclopride continuous infusion PET scans , 1999, Synapse.
[71] J. Coyle,et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. , 1999, Archives of general psychiatry.
[72] Christer Halldin,et al. PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 , 1998, NeuroImage.
[73] Paul J. Harrison. The neuropathology of schizophrenia , 2008 .
[74] M Laruelle,et al. Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.
[75] R. Roth,et al. The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.
[76] J. Hietala,et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia , 1999, Schizophrenia Research.
[77] D. Javitt,et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.
[78] A. Carlsson,et al. Neurotransmitter interactions in schizophrenia—therapeutic implications , 1999, Biological Psychiatry.
[79] M. Bergström,et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(β-11C) DOPA and PET , 1999, Biological Psychiatry.
[80] M. Laruelle,et al. Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.
[81] S. Ahlénius. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. , 1999, Pharmacology & toxicology.
[82] R. Huganir,et al. Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs , 2000, The Journal of Neuroscience.
[83] M. Pistis,et al. Dissociation of Haloperidol, Clozapine, and Olanzapine Effects on Electrical Activity of Mesocortical Dopamine Neurons and Dopamine Release in the Prefrontal Cortex , 2000, Neuropsychopharmacology.
[84] R. V. Van Heertum,et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[85] F. Mora,et al. Endogenous dopamine potentiates the effects of glutamate on extracellular GABA in the prefrontal cortex of the freely moving rat , 2000, Brain Research Bulletin.
[86] M. Laruelle,et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.
[87] J. Meador-Woodruff,et al. Glutamate receptor expression in schizophrenic brain , 2000, Brain Research Reviews.
[88] Christer Halldin,et al. Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[89] P. Goldman-Rakic,et al. D1 receptors in prefrontal cells and circuits , 2000, Brain Research Reviews.
[90] Marc Laruelle,et al. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies , 2000, Brain Research Reviews.
[91] M. Laruelle. Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[92] R. Malenka,et al. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. , 2000, Annual review of neuroscience.
[93] A. Grace,et al. Dopamine-mediated regulation of striatal neuronal and network interactions , 2000, Trends in Neurosciences.
[94] S. Sesack,et al. Projections from the Rat Prefrontal Cortex to the Ventral Tegmental Area: Target Specificity in the Synaptic Associations with Mesoaccumbens and Mesocortical Neurons , 2000, The Journal of Neuroscience.
[95] B. Moghaddam,et al. Target‐Specific Glutamatergic Regulation of Dopamine Neurons in the Ventral Tegmental Area , 2000, Journal of neurochemistry.
[96] D Hell,et al. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. , 2000, Journal of psychiatric research.
[97] P. Calabresi,et al. Dopaminergic control of synaptic plasticity in the dorsal striatum , 2001, The European journal of neuroscience.
[98] R. Parsey,et al. Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression , 2001, Biological Psychiatry.
[99] D. Durstewitz,et al. Bidirectional Dopamine Modulation of GABAergic Inhibition in Prefrontal Cortical Pyramidal Neurons , 2001, The Journal of Neuroscience.
[100] M. Jackson,et al. Stimulation of prefrontal cortex at physiologically relevant frequencies inhibits dopamine release in the nucleus accumbens , 2001, Journal of neurochemistry.
[101] T. Sejnowski,et al. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[102] C. Tamminga,et al. Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.
[103] M. Low,et al. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. , 2001, Journal of neurophysiology.
[104] D. Standaert,et al. Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane , 2001, The Journal of Neuroscience.
[105] J. Coyle,et al. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.
[106] H. Wikström,et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. , 2001, European journal of pharmacology.
[107] D. Javitt,et al. Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, International Journal of Neuropsychopharmacology.
[108] H. Meltzer,et al. 5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release , 2001, Journal of neurochemistry.
[109] D. Schoepp. Metabotropic glutamate receptors , 2002, Pharmacology Biochemistry and Behavior.
[110] Paul Greengard,et al. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. , 2002, Journal of neurophysiology.
[111] J. Hirvonen,et al. Ketamine does not decrease striatal dopamine D2 receptor binding in man , 2002, Psychopharmacology.
[112] R. V. Van Heertum,et al. NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans , 2002, Synapse.
[113] Anthony A Grace,et al. Opposite Influences of Endogenous Dopamine D1 and D2 Receptor Activation on Activity States and Electrophysiological Properties of Striatal Neurons: Studies CombiningIn Vivo Intracellular Recordings and Reverse Microdialysis , 2002, The Journal of Neuroscience.
[114] M. Morari,et al. Striatal dopamine–NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors , 2002, Journal of neurochemistry.
[115] Enhanced amphetamine-induced striatal [11C]raclopride displacement by the group II metabotropic glutamate receptor agonist LY354740 in baboons , 2002, European Neuropsychopharmacology.
[116] R. V. Van Heertum,et al. Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.
[117] G. Sedvall,et al. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. , 2002, The American journal of psychiatry.
[118] M. Millan. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. , 2002, Current drug targets. CNS and neurological disorders.
[119] D. Javitt,et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. , 2002, The American journal of psychiatry.
[120] A. Meyer-Lindenberg,et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.
[121] B. Moghaddam,et al. NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys , 2002, Synapse.
[122] Jeremy K Seamans,et al. Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex. , 2002, Journal of neurophysiology.
[123] Stephan Heckers,et al. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. , 2003, Pharmacology & therapeutics.
[124] Marc Laruelle,et al. The Synaptic Hypothesis of Schizophrenia , 2003, Neuron.
[125] Nicola Pavese,et al. Endogenous dopamine release after pharmacological challenges in Parkinson's disease , 2003, Annals of neurology.
[126] B. Bunney,et al. d-Amphetamine-induced depression of central dopamine neurons: Evidence for mediation by both autoreceptors and a striato-nigral feedback pathway , 1978, Naunyn-Schmiedeberg's Archives of Pharmacology.
[127] J. Lieberman,et al. Provocative tests with psychostimulant drugs in schizophrenia , 2004, Psychopharmacology.
[128] G. Sedvall,et al. Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients , 1995, Psychopharmacology.
[129] D. Naber,et al. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states , 1995, Psychopharmacology.
[130] H. Fukuda,et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography , 2005, Psychopharmacology.
[131] H. Lublin,et al. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia , 1995, Psychopharmacology.
[132] H. Westenberg,et al. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia , 1995, Psychopharmacology.